Last reviewed · How we verify
NCT04637672: MASC
Clinical Database and Biobank of Patients With Inflammatory Myopathies: the MASC Project (Myositis, DNA, Serum, Cells) (MASC)
trial in Inflammatory Myositis in 1,273 participants. Completed in 14 December 2023.
14 December 2023
Quick facts
| Lead sponsor | Groupe Hospitalier Pitie-Salpetriere |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,273 |
| Start date | 19 December 2013 |
| Primary completion | 14 December 2023 |
| Estimated completion | 14 December 2023 |
| Sites | 1 location across France |
Conditions studied
- Inflammatory Myositis — all drugs for Inflammatory Myositis →
- Idiopathic Inflammatory Myositis — all drugs for Idiopathic Inflammatory Myositis →
- Drug-induced Inflammatory Myositis — all drugs for Drug-induced Inflammatory Myositis →
Sponsor
Groupe Hospitalier Pitie-Salpetriere
Who can join
18 and older, any sex, with Inflammatory Myositis or Idiopathic Inflammatory Myositis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Myositis are rare diseases for which the development of a cohort associated with a bank of biological samples (biobank) will allow for the conduct of researches to better delineate the underlying pathophysiology and find cures. This prospective cohort of patients with myositis will allow for identification of factors favouring the occurrence of myositis, whether they are constitutional (genetic) or acquired (environmental or drug). Different subgroups of myositis used for prognostication will be identified based on clinico-demographical variables, the nature of the organs involved beyond peripheral muscles (cardiac, diaphragm) and biomarkers abnormalities.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.
Lehmann LH, Heckmann MB, Bailly G, Finke D, et al · · 2023 · cited 106× · PMID 37317858 · DOI 10.1161/circulationaha.123.062405 -
Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature.
Demortier J, Vautier M, Chosidow O, Gallay L, et al · · 2023 · cited 19× · PMID 37010495 · DOI 10.1093/rheumatology/kead154 -
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
Puszkiel A, Bianconi G, Pasquiers B, Balakirouchenane D, et al · · 2024 · cited 9× · PMID 38532102 · DOI 10.1038/s41416-024-02659-x -
Myostatin in idiopathic inflammatory myopathies: Serum assessment and disease activity.
Mahoudeau A, Anquetil C, Tawara N, Khademian H, et al · · 2023 · cited 5× · PMID 36168256 · DOI 10.1111/nan.12849 -
Prognostic factors for patients with cancer-associated dermatomyositis: a retrospective, multicentre cohort study of 73 patients.
Teboul A, Allenbach Y, Tubach F, Belin L, et al · · 2025 · cited 3× · PMID 39589730 · DOI 10.1093/rheumatology/keae629 -
Complement-independent pathogenic influences of anti-HMGCR + and anti-SRP + immune-mediated necrotizing myopathy autoantibodies on engineered muscle function.
Lad H, Tiper Y, Esteban EM, Singh MK, et al · · 2025 · cited 1× · PMID 41287112 · DOI 10.1186/s13395-025-00400-7
Verify or expand the search:
- PubMed search for NCT04637672
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Inflammatory Myositis
Currently open trials in the same condition.
- NCT06593041 — ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS · recruiting
- NCT05454527 — Follow-up of Patients With Inflammatory Myopathies Associated With a Biobank · recruiting
Other Groupe Hospitalier Pitie-Salpetriere trials
Trials by the same sponsor.
- NCT06515678 — Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension · active not recruiting
- NCT05934214 — EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Databa · completed
- NCT05819736 — Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients · unknown
- NCT04320017 — Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observa · completed
- NCT04314817 — Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04637672 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier Pitie-Salpetriere
- Last refreshed: 22 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04637672.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing